Wednesday, July 12, 2023 @ 1:00 PM EASTERN

This webinar chaired by Dr. Ira Bleiwess, Chief of Breast Pathology at the University of Pennsylvania, and Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, will feature expert pathology and oncology perspectives on the management of triple-negative breast cancer (TNBC), including case explorations and insights into frequently asked questions. Register today to hear these expert perspectives!

Gain expert insights into the use of BCMA-directed agents, a promising therapy class for patients with relapsed/refractory multiple myeloma. Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Fred Hutchinson Cancer Center, will provide a case-based discussion on leveraging BCMA-directed antibody-drug conjugates, CAR T-cell therapies, and bispecific T-cell engagers to improve outcomes for patients with multiple myeloma in need of additional treatment options. Start the activity now!

In this activity, discover new insights and real-world evidence for improved patient outcomes in recurrent/metastatic head and neck squamous cell carcinoma from Dr. Assuntina G. Sacco, Associate Professor of Internal Medicine at the University of California, San Diego Health. Learn about differing therapeutic strategies based on tumor location and stage, human papillomavirus (HPV) status, the need to preserve surrounding organs and tissues, impacts on quality of life, and more. Start the activity now!

In this activity, explore new treatment advances for acid sphingomyelinase deficiency (ASMD) in adults with Neal Weinreb, Voluntary Associate Professor for Human Genetics at the University of Miami, Miller School of Medicine. Learn about diagnosis, counseling points, and the recent approval of the first acid sphingomyelinase (ASM) enzyme replacement therapy, which presents the first opportunity to address the pathology underlying this condition. Start the activity now!

In this Virtual Tumor Board, discover strategies for building comprehensive care plans for patients with esophagogastric cancers from Dr. Jaffer Ajani, Professor of Gastrointestinal Medical Oncology at MD Anderson Cancer Center; Dr. Lei Zhao, Assistant Professor of Pathology at Brigham and Women's Hospital; and Dr. Kelley Rone, Advanced Practice Nurse in Gastrointestinal Oncology at the Mayo Clinic. Start the activity now to hear their case-based discussion for the multidisciplinary team!

In this case-based discussion, discover recent clinical trial findings on checkpoint inhibitors and VEGFR-directed therapies that can inform personalized care plans for patients with renal cell carcinoma (RCC). Dr. Eric Jonasch, Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, will provide expert perspectives on the myriad of novel therapeutic options for advanced RCC. Start the activity now!

Gain expert insights on evolving treatment paradigms in castration-sensitive and castration-resistant prostate cancer in this activity presented by Dr. Tanya Dorff, Associate Professor of Medicine and Section Chief of the Genitourinary Cancers Program at City of Hope. Learners will be able to incorporate emerging efficacy and safety data on novel therapeutic strategies into personalized care plans designed to optimize disease control and survival. Start the activity now!

In this session, Constance Visovsky, PhD, RN, ACNP, FAAN, Director and the Lewis & Leona Hughes Endowed Chair of the College of Nursing at the University of South Florida, will clarify the mechanism by which CDK4/6 inhibitors in combination with endocrine therapy are thought to overcome resistance to endocrine therapy in ER-positive metastatic breast cancer, including the data that led to the approval of abemaciclib in the early-stage breast cancer setting, as well as early and aggressive identification of side effects to minimize toxicity.

In this session, Julia A. LaBarbera, MSN, RN, AGACNP-BC, Nurse Practitioner in Hematology/Oncology at UCLA Health in Santa Monica, California, will discuss the increasing use of antibody-drug conjugates in breast cancer, including the approval of sacituzumab govitecan and the expanded approval of trastuzumab deruxtecan for HER2-low breast cancer, as well as monitoring for and managing the unique side effects of these highly efficacious treatments. Start the activity now!

In this session, Julia A. LaBarbera, MSN, RN, AGACNP-BC, Nurse Practitioner in Hematology/Oncology at UCLA Health in Santa Monica, will explore the uses of immune checkpoint inhibition, a therapeutic strategy which is moving to earlier settings in breast cancer, including preoperative therapy with pembrolizumab/chemotherapy. The discussion will include an overview of immune-mediated adverse events and how they can be graded and managed. Start the activity now!

In this session, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at Saint Luke’s Hospital, Kansas City, Missouri, will explain the benefit of PARP inhibitors for breast cancer in patients with germline BRCA mutations and will present the latest data justifying the recent approval of olaparib for adjuvant therapy in high-risk early breast cancer. She will also highlight the side effect profiles of PARP inhibitors and the importance of counseling patients about the side effects they may experience. Start the activity now!

In this session, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at Saint Luke’s Hospital, Kansas City, Missouri, will explore the role of PI3K inhibitors for patients with a mutation in PIK3CA nd HR-positive, HER2-negative breast cancer, including alpelisib. She will explain how PI3K inhibition is thought to help overcome resistance to hormonal therapy for breast cancer and will review the safety concerns associated with PI3K agents. Start the activity now!

In this session, Abbey Kaler, MS, APRN, FNP-C, Advanced Practice Registered Nurse in the Advanced Breast Cancer Program at the University of Texas MD Anderson Cancer Center, will review the current options for treatment of HER2-positive breast cancer using HER2-targeted monoclonal antibodies, including the advantages and disadvantages regarding the combination of trastuzumab/pertuzumab/hyaluronidase, the indications for margetuximab, and the latest guidance on managing cardiac and other adverse events with HER2-targeted monoclonal antibody therapy. Start the activity now!

In this session, Abbey Kaler, MS, APRN, FNP-C, Advanced Practice Registered Nurse in the Advanced Breast Cancer Program at the University of Texas MD Anderson Cancer Center, will review data on HER2 tyrosine kinase inhibitors, including tucatinib and neratinib, and will compare their activity and safety profiles in combination with other medications for breast cancer. She will also highlight the differing considerations for management of patients taking these drugs. Start the activity now!

This case-based discussion brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care. Start the activity now.

Gain expert insight and enhance your clinical knowledge with this case-based activity focusing on new and groundbreaking biomarkers used for diagnosis of graft-versus-host disease, factors for therapy selection, and clinical trial findings used to individualized treatment for patents, presented by leading faculty Shernan Holtan, MD, Associate Professor of Medicine, University of Minnesota, and Carrie Kitko, MD, Associate Professor of Pediatrics, Vanderbilt University Medical Center. Start the activity now!

Presented by Dr. Shawn Kwatra, Director, Johns Hopkins Itch Center, Associate Professor of Dermatology, Johns Hopkins University School of Medicine and Dr. Linda Stein Gold, Director of Dermatology Clinical Research, Division Head of Dermatology, Henry Ford Health System, this expert-led discussion will direct thoughtful consideration of the health care disparities faced by Black patients with AD, best practices in diagnosis and assessment, and the applicability of novel therapeutic approaches for moderate-to-severe disease. Start the activity now!

This expert-led discussion presented by Aaron Goodman, MD, Hematologist/Oncologist and Associate Professor of Medicine at UC San Diego Health provides the latest insights on diagnosing T-cell lymphoma, including subtypes; efficacy and safety data for novel agents; tailoring treatment plans to individual patients; applying strategies to manage symptoms and optimize a patient’s quality of life; and much more! Start the activity now!

Learn more about myelofibrosis risk factors, novel therapies to slow disease progression and reduce symptoms, and strategies to maintain quality of life in this comprehensive activity presented by John Mascarenhas, MD, Professor of Medicine at Mount Sinai Icahn School of Medicine. Start the activity now!